System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Andreas Dietz is an expert in Oncology at University Hospital Leipzig (Germany). As of October 2026, ScienceLeadR ranks Andreas Dietz in the top 1% of experts worldwide for Squamous Cell Carcinoma of Head and Neck, Otorhinolaryngologic Neoplasms and Carcinoma. Andreas Dietz has authored 764 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 8 of them ongoing. SLR score: 2,146 (community average: 125). How the SLR is computed.

LeadR Profile

Andreas Dietz University Hospital Leipzig Germany
2 146 ScienceLeadR Reputation 2146

Unlock

Register Login
Network Map

Oncology

Subspecialties: Otolaryngology - Medical Imaging - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Since April 2004, Prof. Dr. Andreas Dietz is Chair of the ENT University Clinic Leipzig. He is full-trained ENT and head and neck surgeon and has special qualification in plastic surgery and Oncology. His scientific work is reflected in numerous studies and translational projects on head and neck cancer.

He is internationally known as an expert in this field. He was President of the German Society for ENT - Head and Neck Surgery (DGHNO-KHT) from 2019 to 2020 and is speaker of the interdisciplinary group of Head and Neck Cancer of the German Cancer Society (IAG-KHT).

He holds visible positions on numerous international committees like membership of the Board of Directors of the European Head and Neck Society. He is speaker of the board of the Innovation Center for Computer-Assisted Surgery (ICCAS) Leipzig. He is a member of the Board of Directors of the Global Online Fellowship Initiative at Sloan Kettering Memorial Cancer Center in New York and conference president of ECHNO 2027 in Berlin.

He is honorary member of the Royal Belgian, the Austrian, Hungarian, Czech ENT Society and the Indian Head and Neck Foundation. Andreas Dietz is author/co-author of more than 600 pub-med listed publications (h-index 58). He coordinates the German S3-Guideline for oropharyngeal and hypopharyngeal cancer. Andreas Dietz was honored with the DGHNO-KHC Medal of Merit, the Order of Merit of the Free State of Saxony in 2022 and with the EHNS Award in 2023.

Organizations

Career arc: 1991 - 2026
Source: PubMed

Leipzig University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 764

Citations

Citations: 14 851 1st author: 91 Last author: 142 Unique author: 91

Main journals

Laryngorhinootologie 237
HNO 82
Eur Arch Otorhinolaryngol 28
Front Oncol 21
Head Neck 16

Best Journals

Lancet Oncol 5
Ann Oncol 2
J Clin Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Reevaluation of the Bayesian network model to support immunotherapy decision-making in recurrent/metastatic head and neck squamous cell carcinoma.
PMID 42789152 — cells, carcinoma, squamous cell, decision making, immunotherapy, squamous cell carcinoma of head and neck, therapeutics		Int J Comput Assist Radiol Surg20260
Diagnosis of tympanic effusions using hyperspectral imaging to prevent unnecessary paracentesis procedures.
PMID 42527904 — injections, diagnostic imaging, diagnosis, paracentesis		BMC Med Imaging20260
The influence of urban versus rural residence and travel distance on net income, out-of-pocket payments and quality of life in German head and neck cancer survivors.
PMID 42471510 — travel, quality of life, financial stress, cancer survivors, neoplasms, income, aftercare, head and neck neoplasms		J Cancer Res Clin Oncol20260
Cancer of unknown primary in the neck-challenging in diagnosis and treatment.
PMID 42305507 — neoplasms, diagnosis, therapeutics		Transl Cancer Res20260
High rate of pulmonary exacerbations and neutrophilic airway inflammation in children with repaired esophageal atresia with or without tracheoesophageal fistula.
PMID 42204366 — dyskinesias, tracheoesophageal fistula, fistula, ciliary motility disorders, esophageal atresia, bronchitis, neutrophils, kartagener syndrome, pediatrics, bacteria, child		Pediatr Res20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1 Study Director: 1

By phase:

Phase 2 9
Phase 3 6
Phase 1/Phase 2 3
N/A 2
Phase 1 1

By status:

Completed 11
Recruiting 6
Terminated 2
Active not recruiting 1
Not yet recruiting 1

By type:

Interventional 20
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 1
multicentricup10 16

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 study to evaluate petosemtamab vs investigator s choice in previously treated metastatic recurrent head and neck cancer
2023-510322-32-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Active not recruiting2025
An extension study to investigate the long term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps
2025-522983-33-00 — safety, polyps, nasal polyps, rhinosinusitis		Phase 3Recruiting2026
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent Metastatic Head and Neck Cancer
2025-521917-24-00 — cells, carcinoma, squamous cell, neoplasms, fluorouracil, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carboplatin, carcinoma, head, neck		Phase 3Not yet recruiting2026
A Phase 1b 2 Open label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants with Head and Neck Squamous Cell Carcinoma
2023-508418-40-00 — cells, paclitaxel, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, therapeutics, carcinoma, head, neck		Phase 1/Phase 2Recruiting2024
European Larynx Organ Preservation Study (ELOS)
2022-502751-61-00 — cells, larynx, organ preservation, docetaxel, induction chemotherapy, carcinoma, squamous cell, laryngectomy, neoplasms, hypopharyngeal neoplasms, biopsy, drug therapy, therapeutics, tissues, chemotherapy, carcinoma		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS